Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus HEMADY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus HEMADY.
AMINOCAPROIC ACID IN PLASTIC CONTAINER vs HEMADY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
HEMADY is a phytonadione (vitamin K1) formulation that promotes hepatic synthesis of clotting factors II, VII, IX, and X, reversing anticoagulation by inhibiting vitamin K epoxide reductase.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
Adult: 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Terminal elimination half-life is 1.2-2 hours in healthy adults; clinically relevant as it requires frequent dosing (every 4-6 hours) for sustained effect.
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Primarily renal excretion of unchanged drug (70-80%), with 20-30% metabolized and excreted as inactive metabolites in urine; less than 5% eliminated in feces via biliary secretion.
Category C
Category C
Antifibrinolytic
Antifibrinolytic